PMID- 25550602 OWN - NLM STAT- MEDLINE DCOM- 20150310 LR - 20221207 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 35 IP - 1 DP - 2015 Jan TI - Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer. PG - 555-62 AB - BACKGROUND/AIM: Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients. MATERIALS AND METHODS: Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry. RESULTS: The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders. CONCLUSION: An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy. CI - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Takakura, Kazuki AU - Takakura K AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Koido, Shigeo AU - Koido S AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo, Japan Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan shigeo_koido@jikei.ac.jp. FAU - Kan, Shin AU - Kan S AD - Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Yoshida, Kosaku AU - Yoshida K AD - Research and Development Division, Tella Inc., Tokyo, Japan. FAU - Mori, Masako AU - Mori M AD - Research and Development Division, Tella Inc., Tokyo, Japan. FAU - Hirano, Yuta AU - Hirano Y AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Ito, Zensho AU - Ito Z AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kobayashi, Hiroko AU - Kobayashi H AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Takami, Shinichiro AU - Takami S AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Matsumoto, Yoshihiro AU - Matsumoto Y AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kajihara, Mikio AU - Kajihara M AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Misawa, Takeyuki AU - Misawa T AD - Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan. FAU - Okamoto, Masato AU - Okamoto M AD - Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, Japan. FAU - Sugiyama, Haruo AU - Sugiyama H AD - Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Osaka, Japan. FAU - Homma, Sadamu AU - Homma S AD - Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan. FAU - Ohkusa, Toshifumi AU - Ohkusa T AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. FAU - Tajiri, Hisao AU - Tajiri H AD - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Biomarkers, Tumor) RN - 0 (Cancer Vaccines) RN - 0 (Cytokines) RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Histocompatibility Antigens Class II) RN - 0 (Peptide Fragments) RN - 0 (WT1 Proteins) RN - 0 (WT1 protein, human) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Adenocarcinoma/immunology/mortality/secondary/*therapy MH - Adult MH - Aged MH - Antimetabolites, Antineoplastic/therapeutic use MH - Biomarkers, Tumor MH - Cancer Vaccines/administration & dosage/*immunology MH - Cells, Cultured MH - Combined Modality Therapy MH - Cytokines/blood MH - Dendritic Cells/immunology/transplantation MH - Deoxycytidine/analogs & derivatives/therapeutic use MH - Female MH - Histocompatibility Antigens Class I/*immunology MH - Histocompatibility Antigens Class II/*immunology MH - Humans MH - Lymphocyte Count MH - Male MH - Middle Aged MH - Neutrophils/immunology MH - Pancreatic Neoplasms/immunology/mortality/pathology/*therapy MH - Peptide Fragments/immunology MH - Prognosis MH - Treatment Outcome MH - Vaccination MH - WT1 Proteins/*immunology MH - Gemcitabine OTO - NOTNLM OT - Cytokine OT - MHC class II OT - WT1 OT - chemoimmunotherapy OT - dendritic cell OT - pancreatic cancer OT - vaccine EDAT- 2015/01/01 06:00 MHDA- 2015/03/11 06:00 CRDT- 2015/01/01 06:00 PHST- 2015/01/01 06:00 [entrez] PHST- 2015/01/01 06:00 [pubmed] PHST- 2015/03/11 06:00 [medline] AID - 35/1/555 [pii] PST - ppublish SO - Anticancer Res. 2015 Jan;35(1):555-62.